Gavi HPV Programs: Application to Implementation

Developing countries disproportionately suffer from the burden of cervical cancer yet lack the resources to establish systematic screening programs that have resulted in significant reductions in morbidity and mortality in developed countries. Human Papillomavirus (HPV) vaccination provides an oppor...

Full description

Bibliographic Details
Main Authors: Celina M. Hanson, Linda Eckert, Paul Bloem, Tania Cernuschi
Format: Article
Language:English
Published: MDPI AG 2015-05-01
Series:Vaccines
Subjects:
HPV
Online Access:http://www.mdpi.com/2076-393X/3/2/408
id doaj-360ed499b1f74cf5a03f8a949ee58480
record_format Article
spelling doaj-360ed499b1f74cf5a03f8a949ee584802020-11-24T23:16:52ZengMDPI AGVaccines2076-393X2015-05-013240841910.3390/vaccines3020408vaccines3020408Gavi HPV Programs: Application to ImplementationCelina M. Hanson0Linda Eckert1Paul Bloem2Tania Cernuschi3Gavi The Vaccine Alliance Secretariat, 2 Chemin des Mines, Geneva 10 CH-1211, SwitzerlandDepartment of Obstetrics and Gynecology, University of Washington, Box 359865, 325 9th Avenue, Seattle, WA 98104, USAWorld Health Organization, Department of Immunization, Vaccines and Biologicals, 20 Avenue Appia, Geneva 27 CH-1211, SwitzerlandWorld Health Organization, Department of Immunization, Vaccines and Biologicals, 20 Avenue Appia, Geneva 27 CH-1211, SwitzerlandDeveloping countries disproportionately suffer from the burden of cervical cancer yet lack the resources to establish systematic screening programs that have resulted in significant reductions in morbidity and mortality in developed countries. Human Papillomavirus (HPV) vaccination provides an opportunity for primary prevention of cervical cancer in low-resource settings through vaccine provision by Gavi The Vaccine Alliance. In addition to the traditional national introduction, countries can apply for a demonstration program to help them make informed decisions for subsequent national introduction. This article summarizes information from approved Gavi HPV demonstration program proposals and preliminary implementation findings. After two rounds of applications, 23 countries have been approved targeting approximately 400,000 girls for vaccination. All countries are proposing primarily school-based strategies with mixed strategies to locate and vaccinate girls not enrolled in school. Experiences to date include: Reaching marginalized girls has been challenging; Strong coordination with the education sector is key and overall acceptance has been high. Initial coverage reports are encouraging but will have to be confirmed in population based coverage surveys that will take place later this year. Experiences from these countries are consistent with existing literature describing other HPV vaccine pilots in low-income settings.http://www.mdpi.com/2076-393X/3/2/408HPVvaccinationcervical cancer
collection DOAJ
language English
format Article
sources DOAJ
author Celina M. Hanson
Linda Eckert
Paul Bloem
Tania Cernuschi
spellingShingle Celina M. Hanson
Linda Eckert
Paul Bloem
Tania Cernuschi
Gavi HPV Programs: Application to Implementation
Vaccines
HPV
vaccination
cervical cancer
author_facet Celina M. Hanson
Linda Eckert
Paul Bloem
Tania Cernuschi
author_sort Celina M. Hanson
title Gavi HPV Programs: Application to Implementation
title_short Gavi HPV Programs: Application to Implementation
title_full Gavi HPV Programs: Application to Implementation
title_fullStr Gavi HPV Programs: Application to Implementation
title_full_unstemmed Gavi HPV Programs: Application to Implementation
title_sort gavi hpv programs: application to implementation
publisher MDPI AG
series Vaccines
issn 2076-393X
publishDate 2015-05-01
description Developing countries disproportionately suffer from the burden of cervical cancer yet lack the resources to establish systematic screening programs that have resulted in significant reductions in morbidity and mortality in developed countries. Human Papillomavirus (HPV) vaccination provides an opportunity for primary prevention of cervical cancer in low-resource settings through vaccine provision by Gavi The Vaccine Alliance. In addition to the traditional national introduction, countries can apply for a demonstration program to help them make informed decisions for subsequent national introduction. This article summarizes information from approved Gavi HPV demonstration program proposals and preliminary implementation findings. After two rounds of applications, 23 countries have been approved targeting approximately 400,000 girls for vaccination. All countries are proposing primarily school-based strategies with mixed strategies to locate and vaccinate girls not enrolled in school. Experiences to date include: Reaching marginalized girls has been challenging; Strong coordination with the education sector is key and overall acceptance has been high. Initial coverage reports are encouraging but will have to be confirmed in population based coverage surveys that will take place later this year. Experiences from these countries are consistent with existing literature describing other HPV vaccine pilots in low-income settings.
topic HPV
vaccination
cervical cancer
url http://www.mdpi.com/2076-393X/3/2/408
work_keys_str_mv AT celinamhanson gavihpvprogramsapplicationtoimplementation
AT lindaeckert gavihpvprogramsapplicationtoimplementation
AT paulbloem gavihpvprogramsapplicationtoimplementation
AT taniacernuschi gavihpvprogramsapplicationtoimplementation
_version_ 1725585923194748928